Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Por um escritor misterioso
Descrição
Frontiers Factors associated with functional disability in patients with acute stroke excluded from alteplase administration due to minor non-disabling neurological deficits
Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers
Acute Ischemic Stroke and Long-Term Outcome After Thrombolysis
Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model, Journal of Nanobiotechnology
Sequential Combination of Intravenous Recombinant Tissue Plasminogen Activator and Intra-Arterial Urokinase in Acute Ischemic Stroke
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke
Reperfusion therapy in acute ischemic stroke: dawn of a new era?, BMC Neurology
%20market-figure-1.png)
Acute Ischemic Stroke (AIS) Market Size and Forecast to 2030
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial - The Lancet Neurology
Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Tissue-type plasminogen activator - Wikipedia
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review, International Journal of Emergency Medicine
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke
de
por adulto (o preço varia de acordo com o tamanho do grupo)
